Multiple System Atrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Report Format: PDF+Excel | Report ID: SR112026A6908

Buy Now Discount
Offer

Market Overview:

The multiple system atrophy market reached a value of USD 138.8 Million across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 207.8 Million by 2036, exhibiting a growth rate (CAGR) of 3.75% during 2026-2036.

Report Attribute	Key Statistics
Base Year	2025
Forecast Years	2026-2036
Historical Years	2020-2025
Market Size in 2025	USD 138.8 Million
Market Forecast in 2036	USD 207.8 Million
Market Growth Rate (2026-2036)	3.75%

The multiple system atrophy market has been comprehensively analyzed in IMARC's new report titled "Multiple System Atrophy Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Multiple system atrophy (MSA) is a rare and progressive neurodegenerative disorder that generally impacts the autonomic nervous system and the motor system. The symptoms of MSA primarily include a combination of indications such as parkinsonism (tremors, stiffness, and slow movements), loss of balance and coordination, difficulty speaking and swallowing, problems with bladder and bowel control, and changes in blood pressure regulation that cause fainting spells. Due to its resemblance to other neurological disorders and the lack of precise diagnostic testing, diagnosing MSA can be difficult. A conclusive diagnosis of MSA usually requires a combination of clinical, neurological, and imaging evaluations. A clinical evaluation includes a detailed medical history, physical examination, and an assessment of the patient's motor function, balance, speech, and cognition. A neurological assessment consists of tests, such as a spinal tap, electroencephalography, and electromyography. Numerous imaging studies, including MRI and PET scans, are utilized to help identify changes in the brain that are characteristic of MSA.

The rising prevalence of neurogenerative disorders along with the increasing unmet clinical need for treatment is primarily driving the global multiple system atrophy market. In addition to this, the introduction of specific diagnostic criteria, such as the MSA consensus criteria, which help to enhance the accuracy of MSA diagnosis and reduce the number of misdiagnoses, is also creating a positive outlook for the market. Besides this, the emerging popularity of non-pharmacological approaches, such as physiotherapy, occupational therapy, and speech therapy, to assist in managing the symptoms and improving the quality of life for people with MSA is also bolstering the global market. Furthermore, several technological advancements in the field of neuroscience, including the introduction of advanced imaging technologies and gene editing, are augmenting the development of novel diagnostic tools and treatments for MSA. This, in turn, is acting as a significant growth-inducing factor. Apart from this, extensive investments in research activities aimed at analyzing the potential of stem cell therapy for regenerating damaged neurons and improving disease symptoms are expected to drive the global multiple system atrophy market in the coming years. IMARC Group's new report provides an exhaustive analysis of the multiple system atrophy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for multiple system atrophy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the multiple system atrophy market in any manner.

Time Period of the Study

Base Year: 2025
Historical Period: 2020-2025
Market Forecast: 2026-2036

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the multiple system atrophy market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the multiple system atrophy market
Reimbursement scenario in the market
In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current multiple system atrophy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Drugs	Company Name
Northera (Droxidopa)	Lundbeck
TAK-341	Takeda Pharmaceutical Company Limited
Amlenetug (Lu AF82422 )	Lundbeck
ATH434	Alterity therapeutics
hOMSC300	Cytora
Emrusolmin (TEV-286)	Teva Pharmaceutical Industries Ltd.

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the multiple system atrophy market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
What was the country-wise size of the multiple system atrophy across the seven major markets in 2025 and what will it look like in 2036?
What is the growth rate of the multiple system atrophy across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2020-2036) of multiple system atrophy across the seven major markets?
What is the number of prevalent cases (2020-2036) of multiple system atrophy by age across the seven major markets?
What is the number of prevalent cases (2020-2036) of multiple system atrophy by gender across the seven major markets?
What is the number of prevalent cases (2020-2036) of multiple system atrophy by type across the seven major markets?
How many patients are diagnosed (2020-2036) with multiple system atrophy across the seven major markets?
What is the size of the multiple system atrophy patient pool (2020-2025) across the seven major markets?
What would be the forecasted patient pool (2026-2036) across the seven major markets?
What are the key factors driving the epidemiological trend multiple system atrophy of?
What will be the growth rate of patients across the seven major markets?

Multiple System Atrophy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for multiple system atrophy drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the multiple system atrophy market?
What are the key regulatory events related to the multiple system atrophy market?
What is the structure of clinical trial landscape by status related to the multiple system atrophy market?
What is the structure of clinical trial landscape by phase related to the multiple system atrophy market?
What is the structure of clinical trial landscape by route of administration related to the multiple system atrophy market?

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Purchase Options Discount
Offer

Inquire Before Buying

Speak to an Analyst

Request Brochure

Request Customization

Benefits of Customization

Personalize this research
Triangulate with your data
Get data as per your format and definition
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-201-971-6302

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: 中国·银河贵宾汇(GALAXY):[email protected]

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

IMARC did an outstanding job in preparing our study. They were punctual and precise, delivering all the data we required in a clear and well-organized format. Their attention to detail and ability to meet deadlines was impressive, making them a reliable partner for our project.

I wanted to express my sincere appreciation for your efforts in handling this matter. Your dedication and commitment have truly been commendable. It is evident that you have put in a tremendous amount of hard work and expertise into resolving the issues at hand. I would also like to take this opportunity to inform you that we are greatly interested

Overall, the deliverable was well organized and my experience with the project team was good. In particular, I appreciated how they responded when I requested additional information and the Japanese version.

The IMARC team were extremely professional and very cooperative. The team were also extremely flexible in making changes and modifications wherever required. The entire experience right from project kick-off to after sales support was fruitful and smooth.

I’d like to express my gratitude for the work you accomplished with the industry report. The way you responded to the requirements and delivered under tight timelines shows your expertise, exceptional work ethic and commitment to your customer’s success. The entire team and company are incredibly thankful for your dedication. Once again, thank you

The market reports from IMARC have been instrumental in guiding our business strategies. We found the reports comprehensive and data-driven, which helped us make informed decisions. The detailed insights and actionable data have consistently provided us with a competitive edge in a rapidly changing alcohol market.

One of the best things about IMARC is their flexibility and predisposition to tailor the reports and adapt to our needs. They are not just great in their researching and consulting solutions, but their service is unparallelled. We’ve worked with them a couple of times and we will keep working with them in future projects.

We recently commissioned multiple market research reports from IMARC, and the insights we received were invaluable. The depth of analysis, accuracy of data, and actionable recommendations have greatly enhanced our strategic decision-making.

The market estimates provided by your team were pretty much in line with what we were theorizing internally. Really appreciate the work on this.

The sale account manager and the service was excellent. The data and market trends gathered from the report was insightful and really assisted while planning future product and growth strategies.

The report is excellent and has good amount of data and our team is extremely happy with the information provided.

Thank you very much for your cooperation and post purchase support. We were really happy with the final deliverable, and the takeaways from the report.